Eucalyptus Oil as Adjuvant Therapy for Coronavirus Disease 19 (COVID-19)
Status:
Completed
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Background :
Based on several clinical trials, eucalyptus oil can suppress edema formation and reduce
inflammation, where the effect of 1,8-cineole is due to the inhibition of cytokine secretion
by T lymphocytes. This but not limited to the reduction of interleukin (IL) of IL-4, IL-5,
and IL-10 in nasal lavage fluids and levels of IL- 1β, IL-6, Tumor Necrosis Factor-α (TNF-α),
and Interferon-γ (IFN-γ) in lung tissue of mice infected with influenza virus. Hence the
researchers assume that Eucalyptus may possess benefits in COVID-19 as adjuvant therapy.
Objectives :
The primary objective of this study is to evaluate the efficacy of Eucalyptus oil as adjuvant
therapy in mild-moderate COVID-19 patients.
Hypothesis :
Eucalyptus oil may reduce the inflammatory cytokines which eventually improves clinical
symptoms